APP and Alzheimer disease: Finally, MR-39 was chronically administered to APP/PS1 mice to address the question of whether the activation of FPR2 has a beneficial effect on neuronal damage, inflammatory response, glial cell activation, and plaque density formation in the frontal cortex and hippocampus, which are the brain areas engaged in AD pathology.